Phase 1 Study of GRT-001 in Healthy Volunteers and Ulcerative Colitis Patients: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Evaluation

The primary objective of this study is to evaluate the **safety**, **tolerability**, **pharmacokinetics**, and **pharmacodynamics** of GRT-001 in both healthy volunteers and patients with **ulcerative colitis**. This is a critical assessment as it provides foundational data on the drug's interaction with the body, its potential side effects, and its overall safety profile, which are essential for determining the feasibility of further clinical development. The study is designed as a randomized, double-blind, placebo-controlled, single-dose-escalation, phase 1 trial, ensuring rigorous evaluation of these parameters.

The clinical trial involves participants diagnosed with **ulcerative colitis**. The study population includes both male and female subjects, with an age range spanning from adolescents to adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection criteria for the trial population have not been disclosed, and no principal inclusion criteria have been specified. The general health status of the participants is not detailed in the available data.

The clinical trial is designed as a **randomized, double-blind, placebo-controlled, single-dose-escalation, phase 1 study**. It aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GRT-001 in both healthy volunteers and patients diagnosed with **ulcerative colitis**. The trial is scheduled to commence on January 1, 2024, with an estimated completion date of December 31, 2025. Participants will be involved in the study for a duration that aligns with the trial's timeline, subject to their continued eligibility and adherence to the study protocol.

The sequence of study visits begins with an inclusion (screening) visit, where potential participants are assessed for eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the investigational product or a placebo. The trial includes multiple follow-up visits to monitor participants' health, collect data on the investigational product's effects, and ensure participant safety. These visits are crucial for assessing the primary and secondary endpoints of the study. The end-of-study visit marks the conclusion of a participant's involvement, where final assessments are conducted, and any remaining study-related procedures are completed.

Participants may be subject to early termination from the study if they experience adverse events that compromise their safety, fail to comply with the study protocol, or withdraw consent. The trial's design ensures that all participants, regardless of group assignment, receive the same level of care and monitoring throughout their involvement. The study's methodology and procedures are structured to maintain the integrity of the data collected and to uphold the ethical standards of clinical research.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of January 1, 2024, and an estimated end date of December 31, 2025. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a systematic approach to collect and analyze data, ensuring that the results are scientifically valid and reliable. The study will adhere to rigorous standards typical of clinical trials to evaluate the efficacy of the investigational product or intervention.